Skip to main content
In stock|Targeted Therapy (Antibody-Drug Conjugate)

Datopotamab Deruxtecan

Oncology TypeSolid Tumour
Drug Class / MechanismADC
No Image
Description

Datopotamab Deruxtecan is classified as an ADC, sourced for use within our Targeted Therapy (Antibody-Drug Conjugate) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy (Antibody-Drug Conjugate)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3